Search company, investor...

Founded Year

2016

Stage

Series C | Alive

Total Raised

$35.41M

Last Raised

$15.91M | 2 yrs ago

About Pharos iBio

Pharos iBio is a drug discovery and development biotech company specializing in analyzing big data based on IT technology. The company uses artificial intelligence techniques to predict the various properties of a compound, and introduces a low-cost and efficient new drug development system. Pharos iBio is focusing on the development of new drugs with orphan and rare diseases, which can shorten the development period and have a high success rate of NDA approval.

Headquarters Location

38, Heungan-daero 427beon-gil, Dongan-gu #1407 & 1408

Anyang, 14059,

South Korea

+82-31-345-6170

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Expert Collections containing Pharos iBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pharos iBio is included in 1 Expert Collection, including Artificial Intelligence.

A

Artificial Intelligence

10,944 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

Pharos iBio Patents

Pharos iBio has filed 5 patents.

The 3 most popular patent topics include:

  • Cancer treatments
  • Chemical bonding
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/29/2019

Radiation therapy, Medical physics, Cancer treatments, Transcription factors, Acute myeloid leukemia

Application

Application Date

5/29/2019

Grant Date

Title

Related Topics

Radiation therapy, Medical physics, Cancer treatments, Transcription factors, Acute myeloid leukemia

Status

Application

Latest Pharos iBio News

Pharos iBio and Johns Hopkins partner in translational AML drug study

Aug 28, 2023

닫기 Pharos iBio, an AI-backed new drug developer based in Korea, said it would conduct a translational study with Johns Hopkins University School of Medicine to develop a combination therapy using its pipeline PHI-101 to treat relapsed or refractory acute myeloid leukemia (AML). A translational study involves the application of findings from basic scientific research to clinical or real-world settings in order to improve medical practice and patient outcomes. Pharos iBio’s corporate identity The Korean company and Donald Small, MD, Ph.D, a professor of pediatric oncology at Johns Hopkins who is a world-renowned expert in AML, will conduct the study to assess the efficacy of PHI-101 in combination with azacitidine (brand name: Vidasa) or venetoclax (brand names: Venclexta and Venclyxto), which are used as the first-line treatment of AML. Professor Small has over 30 years of research experience with FLT3, the target protein of PHI-101, and has led clinical studies of several FLT3 inhibitors in development, Pharos iBio said. He is also advising on the design and the U.S. clinical hospital network for the PHI-101 global phase 2 clinical trial in the U.S. The ongoing PHI-101 clinical trial is in a multinational phase 1b study in AML patients who have not responded to other existing drugs or whose disease has relapsed after treatment. On Aug. 2, Pharos iBio received approval from the Ministry of Food and Drug Safety “for the therapeutic use” of PHI-101 to treat relapsed or refractory AML. The therapeutic use approval allowed the Catholic University of Korea Seoul St. Mary’s Hospital, the applicant, to treat  patients with relapsed or refractory AML on an individual basis. Pharos iBio has expanded the indications for PHI-101 by utilizing its AI-powered drug discovery platform, “Chemiverse.” Chemiverse utilizes the latest AI algorithms such as transformer generation models and big data of approximately 6.2 billion protein 3D structures and compounds. It is used in Pharos iBio's in-house drug discovery process to predict new targets, identify candidates, and expand indications. The Korean company is using Chemiverse to work on PHI-101 targeting AML, recurrent ovarian cancer, triple-negative breast cancer, and as a radiosensitizer. "PHI-101 for AML is our flagship pipeline, and we are preparing for a global phase 2 clinical trial, including the U.S., Australia, and Korea, targeted for the first half of 2024,” said Yoon Jeong-Hyuk Yoon, CEO of Pharos iBio. "The combination therapy translational study with Johns Hopkins University School of Medicine is also part of our 'One Source Multi-Use' strategy." Shares of Pharos iBio, listed on Kosdaq,  were down 2.8 percent to trade at 15,270 won  ($11.54) as of 11:28 a.m., Monday.

Pharos iBio Frequently Asked Questions (FAQ)

  • When was Pharos iBio founded?

    Pharos iBio was founded in 2016.

  • Where is Pharos iBio's headquarters?

    Pharos iBio's headquarters is located at 38, Heungan-daero 427beon-gil, Dongan-gu, Anyang.

  • What is Pharos iBio's latest funding round?

    Pharos iBio's latest funding round is Series C.

  • How much did Pharos iBio raise?

    Pharos iBio raised a total of $35.41M.

  • Who are the investors of Pharos iBio?

    Investors of Pharos iBio include Company K Partners, Intops Investment, LSK Investment, Solidus Investment, TIMEFOLIO Asset Management and 12 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.